KALRAY
Kalray (Euronext Growth Paris: ALKAL), a leader in hardware and software technologies dedicated to data management and data intensive processing from cloud to edge, today announced a strategic collaboration with Arm to deliver ultra-high performance data processing and AI capabilities across a broad set of applications, leveraging Kalray’s industry leading data processing unit (DPU) technology and Arm’s robust partner ecosystem.
The ever-increasing demand for advanced data processing and AI capabilities has become a cornerstone of modern applications, ranging from storage and networking appliances to data center servers and edge computing, such as smart vision systems or telecom solutions.
This diverse application spectrum requires innovative solutions that can manage increasing data and processing requirements while delivering peak performance and high levels of power and cost efficiency. The combination of Kalray’s advanced AI and data processing acceleration capabilities paired with the broad Arm partner ecosystem will make high performance solutions for hardware and software developers across global enterprises more accessible.
In practical terms, this collaboration translates into Kalray integrating Arm® Neoverse™ Coherent Mesh Network (CMN) interconnect technology into Kalray’s next generation data processing and AI accelerator chiplet (code named “Dolomites”). This will enable the connection of Kalray’s DPU to Arm-based chiplets1 using the Arm CMN interconnect, delivered in the same package. It’s an innovative approach that optimizes flexibility, performance, power consumption, and cost efficiency; and it’s aimed at opening new horizons for a wide ecosystem of software developers, enabling them to leverage Kalray’s advanced processor capabilities to drive innovation across multitudes of applications.
“We couldn’t be more thrilled to collaborate with Arm and to bring the unique AI and data intensive processing capabilities offered by our DPU technology to the global Arm ecosystem,” said Eric Baissus, Kalray CEO. “This is a visionary step towards shaping the future of AI processing, making it more accessible, efficient, and powerful for a wider range of applications."
“AI is becoming integral to the entire compute infrastructure, driving an insatiable demand for more data and more computing power,” said Dermot O’Driscoll, vice president of product solutions, Infrastructure Line of Business, Arm. “By leveraging Arm’s CMN interconnect technology, Kalray is making its data acceleration solutions accessible across Arm’s global ecosystem and we look forward to this collaboration sparking new and impactful innovation for the era of AI.”
“This announcement maps to our expectation of increasing data processing solutions that address the expanding set of AI workloads,” said Howard Holton, chief technology officer, GigaOm. “The combination of Arm’s unique ecosystem and Kalray’s innovative DPU technology has the potential to bring the best of two worlds together at a time when the market has an insatiable appetite for data intensive processing.”
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data-centric computing markets, from cloud to edge.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented data processing unit (DPU) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, media & entertainment, life sciences, scientific research, edge computing, automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
ABOUT ARM
Arm technology is building the future of computing. Its energy-efficient processor designs and software platforms have enabled advanced computing in more than 270 billion chips and its technologies securely power products from the sensor to the smartphone and the supercomputer. Together with 1,000+ technology partners, Arm is enabling artificial intelligence to work everywhere, and in cybersecurity, it is delivering the foundation for trust in the digital world – from chip to cloud. The future is being built on Arm.
1 A chiplet is a discrete unpackaged die that can be assembled into a package with other chiplets and assembled into a single processor chip. This new approach enables the development of processors that combine multiple chiplets, offering gains in flexibility and efficiency compared to traditional approaches.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240207386465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom